Has Roy Orden, MD received payments from drug or device companies?

Yes. Drug and device makers reported $57,324 in general payments to Roy Orden, MD across 648 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roy Orden, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roy Orden, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roy Orden, MD

Allergy · Walnut Creek, CANPI 1861781056

Payments from drug & device makers

$57,324in general payments, 2019–2025

Across 648 payments — averaging $88.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optinose US, Inc.$37K
Consortium Of Independent Immunology Clinics, LLC$5K
Sanofi$2K
AstraZeneca$2K
GSK$2K
Regeneron Healthcare Solutions, Inc.$1K
plus $8K from 34 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optinose US, Inc.	39	$37,393
Consortium Of Independent Immunology Clinics, LLC	2	$4,891
Sanofi	49	$2,141
AstraZeneca	71	$2,104
GSK	105	$1,942
Regeneron Healthcare Solutions, Inc.	37	$1,155
Takeda Pharmaceuticals U.S.A., Inc.	42	$970
Alk-abello, Inc	37	$714
Kaleo, Inc.	29	$660
Amgen(2 entities)	38	$616
Pharming Healthcare, Inc.	12	$557
Boehringer Ingelheim	27	$516
Novartis	19	$423
CSL Behring	16	$384
Teva Pharmaceuticals USA, Inc.	25	$343
ARS Pharmaceuticals Operations, Inc.	12	$328
Grifols USA, LLC	12	$283
Genentech USA, Inc.	12	$282
Covis Pharma GmbH	7	$152
Octapharma USA, Inc.	3	$136
Sanofi-aventis U.S. LLC	2	$120
Pfizer	7	$116
LEO Pharma Inc.	5	$108
Ionis Pharmaceuticals, Inc.	3	$101
Biocryst US Sales Co., LLC	5	$92
Blueprint Medicines Corporation	3	$92
Shire North American Group Inc	4	$85
Lilly USA, LLC	3	$81
Galderma Laboratories, L.p.	3	$79
Tersera Therapeutics LLC	2	$71
Hikma Pharmaceuticals USA	3	$71
Genentech, Inc.	1	$68
USWM, LLC	2	$46
Biocryst Pharmaceuticals, Inc.	2	$41
Eyevance Pharmaceuticals LLC	2	$35
ADMA Biomanufacturing LLC	2	$33
Paratek Pharmaceuticals, Inc.	2	$33
Kowa Pharmaceuticals America, Inc.	1	$24
Phadia US Inc.	1	$22
Merck	1	$17

How this compares

$57,324 in reported general payments places this provider in the 90th percentile of 117 allergy providers in California.

See all allergy providers in California →

Medicare billing

Part B allowed, 2024

$370,141

Medicare patients

198

Services billed

12,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other allergy in Walnut Creek

Joshua JacobsWalnut Creek$5.1M
Kelsey IgeWalnut Creek$7K
Shilpi AnandWalnut Creek$5K
Ricardo TanLos Angeles$11.2M
Warner CarrLaguna Niguel$2.4M
William BergerMission Viejo$976K
Robert ZeigerSan Diego$722K
Bradley ChippsSacramento$712K
Travis MillerRoseville$277K
Sarah FieldOrange$271K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →